Abstract
EE55 Cost-Effectiveness of ESMO-Recommended Lenvatinib and Pembrolizumab Regimen as Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: A Comparison With NCCN Recommendations
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have